Specifically, cells resistant to gefitinib have higher lipid droplet content and SCD1 expression levels than gefitinib-sensitive cells in non-small cell lung cancer cell lines and patient tissues (Q et al., 2019). This evidence concerns the gene SCD and non-small cell lung carcinoma.